Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · IEX Real-Time Price · USD
16.60
+0.16 (0.97%)
Jul 12, 2024, 4:00 PM EDT - Market closed

Avadel Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2000
Revenue
55.1427.960022.3359.22
Upgrade
Revenue Growth (YoY)
-----62.28%-42.66%
Upgrade
Cost of Revenue
2.370.85005.7412.13
Upgrade
Gross Profit
52.7727.120016.5947.09
Upgrade
Selling, General & Admin
175.86151.7174.5268.532.4130.18
Upgrade
Research & Development
12.513.2620.717.120.4432.92
Upgrade
Other Operating Expenses
003.35-0.05-45.47.26
Upgrade
Operating Expenses
188.36164.9798.5685.557.4570.36
Upgrade
Operating Income
-135.59-137.85-98.56-85.559.14-23.27
Upgrade
Interest Expense / Income
9.229.8912.349.9412.9912.48
Upgrade
Other Expense / Income
11.8613.040.54-2.341.232.83
Upgrade
Pretax Income
-156.66-160.78-111.44-93.15-5.08-38.58
Upgrade
Income Tax
0.17-0.526.03-15.82-12.11-5.36
Upgrade
Net Income
-156.83-160.28-137.46-77.337.03-33.23
Upgrade
Shares Outstanding (Basic)
928060595337
Upgrade
Shares Outstanding (Diluted)
928060595537
Upgrade
Shares Change
43.53%33.41%2.66%6.54%46.89%0.21%
Upgrade
EPS (Basic)
-1.83-2.00-2.29-1.320.13-0.89
Upgrade
EPS (Diluted)
-1.83-2.00-2.29-1.320.13-0.89
Upgrade
Free Cash Flow
-127.98-128.51-71.02-77.34-48.83-38.2
Upgrade
Free Cash Flow Per Share
-1.40-1.60-1.18-1.32-0.92-1.02
Upgrade
Gross Margin
95.71%96.97%--74.29%79.52%
Upgrade
Operating Margin
-245.89%-492.97%--40.93%-39.29%
Upgrade
Profit Margin
-284.42%-573.17%--31.47%-56.11%
Upgrade
Free Cash Flow Margin
-232.10%-459.58%---218.64%-64.51%
Upgrade
EBITDA
-145.72-149.13-97.6-82.399.6-23.61
Upgrade
EBITDA Margin
-264.28%-533.29%--42.99%-39.88%
Upgrade
Depreciation & Amortization
1.721.771.490.821.692.49
Upgrade
EBIT
-147.44-150.89-99.1-83.27.91-26.1
Upgrade
EBIT Margin
-267.39%-539.61%--35.43%-44.07%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).